adagrasib
mirati
['krystal-1', 'sclc', 'nsclc', 'adagrasib']
 #asco2022 presented the ph2 krystal-1 trial on activity and safety of adagrasib in previously tx patients with advanced krasg12c #nsclc and showed an orr = 43%, dcr = 80%, mpfs=6.5 mos, os =12.6 mos, and was tolerated.
Dir. STEM Workforce Initiatives @LUNGevity. #BME, #Cancer, #Genomics, Dig. #Pathology, jujitsu, and outreach. Thoughts are my own. RT or follow != endorsement.